 |
市場調査レポート
商品コード
1458142
ウシ胎児血清の世界市場規模、シェア、成長分析：エンドユーザー別、用途別 - 産業予測（2024～2031年）Global Fetal Bovine Serum Market Size, Share, Growth Analysis, By End-user(Pharmaceutical & Biotechnology Companies, Contract & Academic Research Organizations), By Application(Drug Discovery, In-vitro Fertilization) - Industry Forecast 2024-2031 |
||||||
| ウシ胎児血清の世界市場規模、シェア、成長分析：エンドユーザー別、用途別 - 産業予測（2024～2031年） |
|
出版日: 2024年03月26日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のウシ胎児血清の市場規模は、2022年に15億7,000万米ドルとなり、予測期間中（2024～2031年）にCAGR14.1%で上昇することにより、2023年の17億9,000万米ドルから、2031年までには51億5,000万米ドルに成長する見通しです。
世界のウシ胎児血清（FBS）市場の主な目的は、生物医学研究開発における最高品質の細胞培養サプリメントに対するニーズの高まりに対応することです。この市場の拡大にはいくつかの要因が寄与しています。第一に、バイオテクノロジーおよび製薬セクター全体の研究開発活動への投資の増加が、FBSの需要を促進しています。第二に、慢性疾患の有病率の増加と効果的な治療ソリューションの必要性から、広範な細胞ベースの研究が必要となり、FBSの需要を押し上げています。しかしながら、世界のウシ胎児血清市場は様々な課題に遭遇しています。重要な課題のひとつは、FBSバッチの品質と組成のばらつきであり、これは研究結果の再現性と信頼性に影響を与えかねません。それにもかかわらず、この市場には成長と革新の機会があります。FBSの代替品として無血清培地や化学的に定義された培地製剤の出現は、動物性成分を含まない細胞培養ソリューションの需要に応える道を市場関係者にもたらします。世界のウシ胎児血清市場は、生物医学研究と細胞培養アプリケーションをサポートする上で極めて重要な役割を担っています。倫理的な懸念、規制上の制限、品質のばらつきに直面しているにもかかわらず、市場は技術革新と代替ソリューションの探求の機会を提供しています。細胞ベースの研究、再生医療、生物製剤に対する需要の高まりが市場を牽引しており、科学的ブレークスルーや治療法の進歩における高品質なFBSの重要性が浮き彫りになっています。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
ウシ胎児血清の世界市場：エンドユーザー別
- 市場概要
- 製薬・バイオテクノロジー企業
- 契約研究機関・学術研究機関
ウシ胎児血清の世界市場：用途別
- 市場概要
- 創薬
- 体外受精
- ワクチンの生産
- 細胞ベース研究
- 診断
- その他
ウシ胎児血清の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Thermo Fisher Scientific Inc.（US）
- Merck KGaA（Germany）
- GE Healthcare（US）
- Tissue Culture Biologicals（US）
- HiMedia Laboratories Pvt. Ltd.（India）
- Atlanta Biologicals Inc.（US）
- Sigma-Aldrich Corporation（US）
- Rocky Mountain Biologicals（US）
- PAN-Biotech GmbH（Germany）
- Bovogen Biologicals Pty Ltd.（Australia）
- Biowest SAS（France）
- Biological Industries Israel Beit Haemek Ltd.（Israel）
- Corning Incorporated（US）
- Sera Laboratories International Ltd.（UK）
- Caisson Laboratories Inc.（US）
- Hyclone Laboratories Inc.（US）
- Lanzhou Minhai Biotechnology Co., Ltd.（China）
- Moregate BioTech（UK）
- Gemini Bio-Products（US）
- Lampire Biological Laboratories（US）
Global Fetal Bovine Serum Market size was valued at USD 1.57 billion in 2022 and is poised to grow from USD 1.79 billion in 2023 to USD 5.15 billion by 2031, by rising at a CAGR of 14.1% during the forecast period (2024-2031).
The primary objective of the global fetal bovine serum (FBS) market is to address the rising need for premium-quality cell culture supplements in biomedical research and development. Several factors contribute to the expansion of this market. Firstly, the growing investments in research and development activities across the biotechnology and pharmaceutical sectors drive the demand for FBS. Secondly, the increasing prevalence of chronic diseases and the imperative for effective therapeutic solutions necessitate extensive cell-based research, thereby boosting the demand for FBS. However, the global fetal bovine serum market encounters various challenges. One significant challenge is the variability in the quality and composition of FBS batches, which can impact the reproducibility and reliability of research outcomes. Nonetheless, the market presents opportunities for growth and innovation. The emergence of serum-free and chemically defined media formulations as substitutes to FBS creates avenues for market players to cater to the demand for animal component-free cell culture solutions. The global fetal bovine serum market holds a pivotal role in supporting biomedical research and cell culture applications. Despite facing ethical concerns, regulatory restrictions, and quality variability, the market offers opportunities for innovation and the exploration of alternative solutions. The escalating demand for cell-based research, regenerative medicine, and biologics drives the market, underscoring the significance of high-quality FBS in advancing scientific breakthroughs and therapeutic advancements.
Top-down and bottom-up approaches were used to estimate and validate the size of the global fetal bovine serum market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Fetal Bovine Serum Market Segmental Analysis
The global fetal bovine serum market is segmented based on end-user, application, and region. By end-user, the market is segmented into pharmaceutical & biotechnology companies, contract & academic research organizations. By application, the market is segmented into drug discovery, in-vitro fertilization, vaccine production, cell-based research, diagnostics, and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Fetal Bovine Serum Market
The biopharmaceutical industry experienced substantial growth, prioritizing the development of innovative therapeutic solutions. Fetal bovine serum (FBS), playing a crucial role in cell culture-based research, saw widespread use in drug discovery, preclinical testing, and biologics production. The heightened investment in biopharmaceutical research and development activities propelled the demand for FBS.
Restraints in the Global Fetal Bovine Serum Market
The utilization of animal-derived products, such as FBS, raised ethical concerns among certain researchers and regulatory bodies. The imperative to minimize or eradicate animal-derived components in cell culture systems prompted the investigation of alternative serum-free and defined media formulations. The presence of these alternatives presented a challenge to the expansion of the FBS market.
Market Trends of the Global Fetal Bovine Serum Market
The industry witnessed a trend towards the creation and adoption of animal component-free culture systems. Researchers and manufacturers aimed to decrease reliance on FBS by transitioning to defined media formulations devoid of animal-derived components. This trend aimed to tackle ethical concerns, improve experimental reproducibility, and streamline regulatory compliance.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Fetal Bovine Serum Market by End-user
- Market Overview
- Pharmaceutical & Biotechnology Companies
- Contract & Academic Research Organizations
Global Fetal Bovine Serum Market by Application
- Market Overview
- Drug Discovery
- In-vitro Fertilization
- Vaccine Production
- Cell-based Research
- Diagnostics
- and Others
Global Fetal Bovine Serum Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GE Healthcare (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Tissue Culture Biologicals (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- HiMedia Laboratories Pvt. Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Atlanta Biologicals Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sigma-Aldrich Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Rocky Mountain Biologicals (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PAN-Biotech GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bovogen Biologicals Pty Ltd. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biowest SAS (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biological Industries Israel Beit Haemek Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Corning Incorporated (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sera Laboratories International Ltd. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Caisson Laboratories Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hyclone Laboratories Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lanzhou Minhai Biotechnology Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Moregate BioTech (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gemini Bio-Products (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lampire Biological Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
